Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

IMproved PREdiction of Severe Sepsis in the Emergency Department (IMPRESSED)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Axis Shield Diagnostics Ltd
ClinicalTrials.gov Identifier:
NCT01392508
First received: July 11, 2011
Last updated: October 25, 2013
Last verified: October 2013

July 11, 2011
October 25, 2013
March 2011
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01392508 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
IMproved PREdiction of Severe Sepsis in the Emergency Department
Prospective, Non-interventional, Multi-centre Clinical Study to Assess the Clinical Validity of the Heparin Binding Protein (HBP) Assay for Indicating the Presence, or Outcome, of Severe Sepsis (Including Septic Shock), Over 72 Hours, in Patients With Suspected Infection Following Emergency Department Admission.

The purposes of this study is to determine whether Heparin Binding Protein (HBP) can be used as a marker of severe sepsis (including septic shock) in patients presenting to the emergency department with suspected infection.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Plasma (LiHep and citrate)

Probability Sample

Patients presenting to emergency department with suspected infection

  • Systemic Inflammatory Response Syndrome (SIRS)
  • Sepsis
  • Severe Sepsis
  • Septic Shock
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
1000
Not Provided
Not Provided

Inclusion Criteria:

  • Greater than or equal to 18 years
  • Suspected Infection
  • one or more SIRS criteria
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Sweden
 
NCT01392508
PEP-FMHBP-001
No
Axis Shield Diagnostics Ltd
Axis Shield Diagnostics Ltd
Not Provided
Principal Investigator: Adam Linder Skanes Universitetssjukhus I Lund, Sweden
Principal Investigator: Magnus Paulsson Skanes universitetssjukhuset i Malmo
Principal Investigator: Patrik Nyberg Universitetssjukhuset i Linkoping
Principal Investigator: Anna Lange-Jendeberg Universitetssjukhuset i Orebro
Principal Investigator: Ryan Arnold The Cooper Health System
Axis Shield Diagnostics Ltd
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP